ExonHit, RedPath Terminate Acquisition Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today announced it is terminating its agreement to buy RedPath Integrated Pathology, following a decision by Medicare to limit its coverage for RedPath's portfolio of tests only to its pancreatic test.

The decision comes after ExonHit and RedPath were unable to agree on revised terms and conditions following the decision by Medicare contractor Highmark Medicare Services to cover only RedPath's TG-Pancreatic cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.